Source comparison
CJC-1295 DAC vs Non-DAC: Different Safety Profiles?
The DAC modification fundamentally changes pharmacokinetics, which in turn affects safety considerations. CJC-1295 with DAC maintains elevated GH and IGF-1 for 6–8 days per injection, creating continuous rather than pulsatile hormone elevation. This mimics exo
This comparison does not assign a generated winner or score.
- The DAC modification fundamentally changes pharmacokinetics, which in turn affects safety considerations. CJC-1295 with DAC maintains elevated GH and IGF-1 for 6–8 days per injection, creating continuous rather than pulsatile hormone elevation. This mimics exogenous GH therapy more than natural GHRH stimulation. CJC-1295 without DAC (Mod GRF 1-29, sometimes called CJC-1295 no DAC) has a half-life of roughly 30 minutes and requires dosing 1–3 times daily to sustain effects.
- No head-to-head safety trial has directly compared the two forms. Theoretically, the non-DAC version preserves more natural pulsatility. GH secretion occurs in discrete bursts aligned with the body's circadian rhythm, peaking during deep sleep. Continuous elevation via DAC could suppress negative feedback loops (somatostatin release from the hypothalamus) or desensitize GHRH receptors over time, though neither effect was documented in the 90-day trials.
- One withdrawn study offers indirect insight. ConjuChem's Phase IIb trial in obesity patients (NCT00345150) tested CJC-1295 DAC weekly for 12 weeks alongside caloric restriction. The trial was terminated early. Not due to adverse events, but because interim efficacy data showed insufficient fat loss compared to diet alone. However, post-trial analysis revealed no difference in adverse event rates between CJC-1295 and placebo groups, and no serious events attributable to the peptide. This unpublished data set, referenced in a 2010 investor briefing, suggests the DAC form's safety profile held even in metabolically compromised populations.
- For researchers working with compounds like those available through Real Peptides, the practical distinction matters: DAC forms allow less frequent dosing but introduce unknowns around chronic elevation; non-DAC forms require stricter dosing schedules but may better mimic physiologic GH patterns. Neither has FDA approval, and both remain classified as research compounds.